Authors : Risha A. Chaudhary; Dr. Pruthviraj K. Chaudhary; Dr. Khushbu Patel; Dr. C. N. Patel

Volume/Issue : Volume 11 - 2026, Issue 1 - January

---

Google Scholar : https://tinyurl.com/yhxk376w

Scribd : https://tinyurl.com/44d5hfzf

DOI : https://doi.org/10.38124/ijisrt/26jan730

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

---

Abstract : Viruses can replicate only within living host cells, as they depend entirely on cellular machinery for their multiplication. According to the type of nucleic acid they contain, viruses are categorized as DNA or RNA viruses. Antiviral medications are developed to suppress viral replication and are classified into agents active against retroviruses and those effective against non-retroviral infections. Although most antiviral drugs are virus-specific, a few demonstrate activity against a wider range of viruses. Molnupiravir is a recently introduced orally administered antiviral agent that is effective against select RNA viruses by disrupting the process of viral RNA synthesis.

Keywords : Molnupiravir, Anti-Viral, Development and Validation, HPLC.

References :

1. Sharma HL, and Sharma K, In Pharmacology, 3^rd ed., Sharma & Sharma’s Paras medical Publisher, Hyderabad, 2017, pp 789.
2. Karan W, Lippincott Illustrated Reviews Pharmacology, 6^th ed., Tata McGraw Hill Publishing Company Limited, New Delhi, 1993, pp 536.
3. KD Tripathi, In Medical Pharmacology, 8^thEd., KDT Jaypee brothers, 2019, pp 849, 861.
4. B.A. Jayk, M.M. Gomes, D.B. Musungaie, E. Kovalchuk, A. Gonzalez and V.D. Reyes, “Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients,” N. Eng. J. of Med., vol. 386(6), pp. 509-520, Dec 2021.
5. B.M. Maas, J. Strizki, R.R. Miller, S. Kumar, M. Brown and M.G. Johnson, “Molnupiravir: Mechanism of action, clinical, and translational science,”, Clin. Transl. Sci., vol. 17(2), pp. 1-8, Feb 2024.
6. DrugBank, “Molnupiravir: Uses, Interactions, Mechanism of Action,”, Sep 2025.       https://go.drugbank.com/drugs/DB15661?utm_source=chatgpt.com
7. S. Islam, N.J. Fariha, S. Ahmed, O. Faruk and S.S. Rouf, “Development and Validation of UV Method for Routine Analysis of Molnupiravir,” Bang. Pharm. J., vol. 28(1), pp. 83-93, Jan 2025.
8. B. Parmar, A. Raj, A. Vasava, V. Chauhan, M. Dalwadi and U. Upadhyay, “Uv Visible Spectroscopy Method Development and Validation for Estimation of Molnupiravir in Solid Dosage Form,” Int. J. of Crea. Res. Tho., vol. 10(4), pp. 812-821, April 2022.
9. M. Deshpande, F. Shaikh, “New UV Spectrophotometric Method for the Estimation of Molnupiravir used in the treatment of COVID-19,” The Open COVID J., vol. 4, pp. 21-29, March 2023.
10. A.M. Annadi, N. M. Elzahar, N.A. Abdel-Sattar, E.H. Mohamed, S.A. Mahmoud and M.S. Attia, “Development and validation of Molnupiravir assessment in bulk powder and pharmaceutical formulation by the RP-HPLC-UV method,” R. Soci. of Chem., vol. 85(4), pp. 903-911, 2025.
11. S. Gandu, K.S. Gandla, and L. Repudi, “New analytical method development and validation for estimation of Molnupiravir in bulk and tablet dosage form by RP-HPLC method,” Cell. Mol. Biomed. Rep., vol. 3(3), pp. 130-136, Sep 2023.
12. G. Kumaraswamy, “A validated stability indicating RP-HPLC method for the determination of Molnupiravir in pharmaceutical dosage form,” Wo. J. of Adv. Res. and Rev., vol. 15(01), pp. 580–590, July 2022.
13. T. Recber, S.S. Timur, S.E. Kablan, F. Yalcin, T.C. Karabulut and R.N. Gursoy “A stability indicating RP-HPLC method for determination of the COVID-19 drug Molnupiravir applied using nano formulations in permeability studies,” J. of Pharma. and Bio. Ana., vol. 214, pp. 1-8, May 2022.
14. M. Deshpande, F. Shaikh, V. Sable and K. Patil, “New Stability Indicating RP-HPLC Method for Estimation of the Drug Molnupiravir,” Int. J. of Pharma. Qua. Ass., vol. 14(1), pp. 149-158 March 2023.
15. S. Akula, M. Sukanya, S. Naga, K.P. Kumar, N. Boggula, and D. Suchirea, “RP-HPLC Method Development and Validation of Molnupiravir in Bulk and Its Pharmaceutical Dosage Form,” Biochem. and Cell. Archives., vol. 25(1), pp. 311, Jan 2025.
16. M.S. Tekade and P.M. Patil, “Stability Indicating HPTLC Method of Molnupiravir and Comparative Study of Degradant with Marketed Molnupiravir Impurity- A,” Ira. J. of Ana. Chem., vol. 9(2), pp. 51-57 Sep 2022.
17. M.A. Moneim, M. Kamal, and M. Hamdy, “Simple Green Spectrophotometric & Chromatographic Assay of the Oral Antiviral Treatment of COVID-19: Molnupiravir.” Egypt. J. of Chem., vol. 66(3), pp. 125-131, March 2023.